<DOC>
	<DOCNO>NCT00307632</DOCNO>
	<brief_summary>The purpose study evaluate contraceptive efficacy , safety , cycle control , compliance , subject satisfaction transdermal contraceptive system , norelgestromine ethinyl estradiol ( NLGM / EE ) .</brief_summary>
	<brief_title>An Open-label Study Evaluate Contraceptive Efficacy Safety Transdermal Contraceptive System Norelgestromine Ethinyl Estradiol</brief_title>
	<detailed_description>A multicenter , open label , descriptive study . Five hundred require contraception receive weekly transdermal contraceptive patch 6 cycle . At baseline 1st , 3rd 6th cycle , satisfaction method assess . The contraceptive efficacy assess Pearl Index life table analysis . To assess satisfaction weekly transdermal contraceptive patch , method compare previous contraceptive method . Adhesion , cycle control , safety efficacy secondary outcome . Treatment duration : 6 cycle ( 4 week ) . The subject wear 20 cm2 contraceptive transdermal patch one full week , apply fresh patch week 2 , third patch week 3 . The fourth week patch-free . Each patch deliveries 150 mcg NLGM 20 mcg EE per day .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Healthy adult female meet follow selection criterion : Have regular menses occur every 2535 day Acceptable body mass ( &lt; 30 ) weight &lt; 90 kg Has complete last term pregnancy least 4 month prior study admission , lactate least one normal menstrual period since last pregnancy breast feeding Has sit blood pressure systolic &lt; 140 mm/Hg diastolic &lt; 90 mm/Hg . Has receive DepoProvera injection depot hormone injection within six month prior screen visit Has use / current use barbiturate , antiepileptic , rifampin , griseofulvin , Hypericum perforatum , hepatic enzymeinducing drug within 30 day prior prestudy visit Has uncontrolled disorder No woman age 35 smoke .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Contraception</keyword>
	<keyword>Hormonal patch</keyword>
	<keyword>Norelgestromine</keyword>
	<keyword>Ethinyl estradiol</keyword>
</DOC>